The stock of Esperion Therapeutics Inc. (NASDAQ:ESPR) decreased by -$0.02 on Wednesday to $1.62, down -1.29 percent. The last five days have seen an average of 1,529,205 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$4.6150. The average number of shares traded over the last 20 days was 2,799,871, while the average volume over the last 50 days totaled 2,891,522.
ESPR stock appreciated 3.11% since last month. On 07/27/23, the company’s shares reached a one-month low of $1.3550. The stock touched a high of $8.87 on 01/10/23, after rallying from a low of $1.12 in 52 weeks. The price of ESPR stock has declined by -74.02% or -$4.6150 this year, reaching a new high 4 times. Still, the stock price is down -81.75% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ESPR stock investors should be aware that Esperion Therapeutics Inc. (ESPR) stock had its last reported insider trading activity 28 days ago on Jul 19. On Jul 19, Chief Commercial Officer Warren Eric sold 106 shares at $1.58 each. This transaction resulted in the insider making $168. On Jun 21, Warren Eric sold 603 shares at a price of US$1.48. After the transaction, the insider now owns 69,409 shares. Chief Commercial Officer Warren Eric had earlier sold 219 shares on May 17 for $1.62 a share. The transaction was completed for $356.
Financial Health
For the three months ended June 29, Esperion Therapeutics Inc.’s quick ratio was 1.70, while its current ratio was 2.20, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 66.90% percent. Based on annual data, it had gross profit of $48.51 million and revenue of $75.47 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ESPR’s return on assets (ROA) during the last 12 months has been -84.90%. There was a 280.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 67.40%.
Earnings Surprise
According to Esperion Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $25.79 million, while revenues rose by 26.95% to $24.33 million. It was predicted that Esperion Therapeutics Inc.’s quarterly earnings would be -$0.46, but it ended up being -$0.61, beating the consensus by 24.60%. EBITDA was -$36.66 million for the quarter. At the end of Esperion Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 606.6 million, while its total debt was $522.9 million. Equity owned by shareholders amounts to $106.99 million.
Technical Picture
Here’s a quick look at Esperion Therapeutics Inc.’s (ESPR) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 50.38%, suggesting the stock is Neutral, with a 100.21% historical volatility rate.
The stochastic %K and %D were 43.12% and 48.84% respectively, while the average true range (ATR) was 0.1310. Based on the 14-day stochastic reading of 36.44%, the RSI (14) reading is 52.20%. On the 9-day MACD Oscillator, the stock is at -0.0011.
Analyst Ratings
In its most recent analyst report, Northland Capital raised its rating on Esperion Therapeutics Inc. (NASDAQ: ESPR) to a Market perform. Prior to this, analysts firm rated the stock as an Under perform. Analysts have assigned Esperion Therapeutics Inc. (ESPR) an Buy rating. ESPR is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.
What is ESPR’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $22.00, with a median target price of $9.00. In analyzing these forecasts, the average price target given by analysts for Esperion Therapeutics Inc. (ESPR) is $10.28.
